TY - JOUR
T1 - Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults
AU - Baillargeon, Jacques
AU - Holmes, Holly M.
AU - Lin, Yu Li
AU - Raji, Mukaila A.
AU - Sharma, Gulshan
AU - Kuo, Yong Fang
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2012/2
Y1 - 2012/2
N2 - Background: Antibiotic medications are associated with an increased risk of bleeding among patients receiving warfarin. The recent availability of data from the Medicare Part D prescription drug program provides an opportunity to assess the association of antibiotic medications and the risk of bleeding in a national population of older adults receiving warfarin. Methods: We conducted a case-control study nested within a cohort of 38,762 patients aged 65 years and older who were continuous warfarin users, using enrollment and claims data for a 5% national sample of Medicare beneficiaries with Part D benefits. Cases were defined as patients hospitalized for a primary diagnosis of bleeding and were matched with 3 control subjects on age, race, sex, and indication for warfarin. Logistic regression analysis was used to calculate adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for the risk of bleeding associated with prior exposure to antibiotic medications. Results: Exposure to any antibiotic agent within the 15 days of the event/index date was associated with an increased risk of bleeding (aOR 2.01; 95% CI, 1.62-2.50). All 6 specific antibiotic drug classes examined (azole antifungals [aOR, 4.57; 95% CI, 1.90-11.03], macrolides [aOR, 1.86; 95% CI, 1.08-3.21], quinolones [aOR, 1.69; 95% CI, 1.09-2.62], cotrimoxazole [aOR, 2.70; 95% CI, 1.46-5.05], penicillins [aOR, 1.92; 95% CI, 1.21-2.07], and cephalosporins [aOR, 2.45; 95% CI, 1.52-3.95]) were associated with an increased risk of bleeding. Conclusion: Among older continuous warfarin users, exposure to antibiotic agentsparticularly azole antifungalswas associated with an increased risk of bleeding.
AB - Background: Antibiotic medications are associated with an increased risk of bleeding among patients receiving warfarin. The recent availability of data from the Medicare Part D prescription drug program provides an opportunity to assess the association of antibiotic medications and the risk of bleeding in a national population of older adults receiving warfarin. Methods: We conducted a case-control study nested within a cohort of 38,762 patients aged 65 years and older who were continuous warfarin users, using enrollment and claims data for a 5% national sample of Medicare beneficiaries with Part D benefits. Cases were defined as patients hospitalized for a primary diagnosis of bleeding and were matched with 3 control subjects on age, race, sex, and indication for warfarin. Logistic regression analysis was used to calculate adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for the risk of bleeding associated with prior exposure to antibiotic medications. Results: Exposure to any antibiotic agent within the 15 days of the event/index date was associated with an increased risk of bleeding (aOR 2.01; 95% CI, 1.62-2.50). All 6 specific antibiotic drug classes examined (azole antifungals [aOR, 4.57; 95% CI, 1.90-11.03], macrolides [aOR, 1.86; 95% CI, 1.08-3.21], quinolones [aOR, 1.69; 95% CI, 1.09-2.62], cotrimoxazole [aOR, 2.70; 95% CI, 1.46-5.05], penicillins [aOR, 1.92; 95% CI, 1.21-2.07], and cephalosporins [aOR, 2.45; 95% CI, 1.52-3.95]) were associated with an increased risk of bleeding. Conclusion: Among older continuous warfarin users, exposure to antibiotic agentsparticularly azole antifungalswas associated with an increased risk of bleeding.
KW - Antibiotics
KW - Major bleeding
KW - Older adults
KW - Patient safety
KW - Pharmacoepidemiology
KW - Warfarin
UR - http://www.scopus.com/inward/record.url?scp=84862937732&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862937732&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2011.08.014
DO - 10.1016/j.amjmed.2011.08.014
M3 - Article
C2 - 22269622
AN - SCOPUS:84862937732
SN - 0002-9343
VL - 125
SP - 183
EP - 189
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 2
ER -